Novartis Entresto® Granted Expanded Indication in Chronic Heart Failure by FDA

Basel, Feb. 16 (Korea Bizwire) — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) [...]